CBIO 1st Efficacy Results For MarzAA In HemA This Week

July 15, 2018

First efficacy data readout coming on July 18, 2018 for MarzAA.

High risk event, but encouraging that press release indicates "demonstrating the efficacy" of MarzAA in HemA.

$CBIO high risk 1st efficacy trial in humans for subQ MarzAA (Factor VIIA)in Hemophilia A on 7/18/18 at scientific meeting. Looking forward to data. Encouraging that press release indicates "demonstrating the efficacy" of MarzAA in Hem A. http://ir.catalystbiosciences.com/phoenix.zhtml?c=254141&p=irol-newsArticle&ID=2357998

Additional disclosure: This post, like all our posts, is not investment advice. We have small position in CBIO going into event as seemingly lower risk due to press release statement. However, we are not committed to CBIO long-term until we see this data.

Share on Facebook
Share on Twitter
Please reload

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services, including our Amp Core™ product, are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action. 

By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here.

Amp Core™ is a trademark of Amp Biotech Research, LLC

©2019 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM